# Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype

> **NCT02135263** · PHASE4 · COMPLETED · sponsor: **Bispebjerg Hospital** · enrollment: 44 (actual)

## Conditions studied

- Carboxylesterase 1 (CES1) Genotype
- CES1 Activity

## Interventions

- **DRUG:** Methylphenidate
- **DRUG:** Enalapril

## Key facts

- **NCT ID:** NCT02135263
- **Lead sponsor:** Bispebjerg Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135263, "Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02135263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*